tak-063
Small moleculeexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2013 (NCT01879722)
Timeline
Indications
Mechanism of action
- Phosphodiesterase 10AINHIBITOR
PDE10A inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- 1-(2-fluoro-4-(1h-pyrazol-1-yl)phenyl)-5-methoxy-3-(1-phenyl-1h-pyrazol-5-yl)pyridazin-4(1h)-one
- tak-063
- tak-063
- tak-063
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02477020 | Phase 2 | Jul 1, 2015 | Takeda |
| NCT02370602 | Phase 1 | Oct 1, 2013 | Takeda |
| NCT01892189 | Phase 1 | Aug 1, 2013 | Takeda |
| NCT01879722 | Phase 1 | Jun 1, 2013 | Takeda |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Takeda | For profit | 4 | 4 | 2 | 2013 |
1 organizations
Page 1 / 1